IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-34580-3.html
   My bibliography  Save this article

Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Author

Listed:
  • Marta Palafox

    (Vall d’Hebron Institute of Oncology)

  • Laia Monserrat

    (Vall d’Hebron Institute of Oncology)

  • Meritxell Bellet

    (Vall d’Hebron Institute of Oncology
    Hospital Vall d’Hebron)

  • Guillermo Villacampa

    (Vall d’Hebron Institute of Oncology)

  • Abel Gonzalez-Perez

    (Institute for Research in Biomedicine (IRB Barcelona)
    Universitat Pompeu Fabra)

  • Mafalda Oliveira

    (Vall d’Hebron Institute of Oncology
    Hospital Vall d’Hebron)

  • Fara Brasó-Maristany

    (August Pi i Sunyer Biomedical Research Institute (IDIBAPS))

  • Nusaibah Ibrahimi

    (Service de Biostatistique et d’Epidémiologie, Gustave Roussy
    University Paris-Saclay)

  • Srinivasaraghavan Kannan

    (Bioinformatics Institute (A*STAR))

  • Leonardo Mina

    (Medica Scientia Innovation Research (MedSIR))

  • Maria Teresa Herrera-Abreu

    (The Breast Cancer Now Research Centre)

  • Andreu Òdena

    (Vall d’Hebron Institute of Oncology)

  • Mònica Sánchez-Guixé

    (Vall d’Hebron Institute of Oncology)

  • Marta Capelán

    (Vall d’Hebron Institute of Oncology
    Hospital Vall d’Hebron)

  • Analía Azaro

    (Vall d’Hebron Institute of Oncology
    Hospital Vall d’Hebron)

  • Alejandra Bruna

    (The Institute of Cancer Research)

  • Olga Rodríguez

    (Vall d’Hebron Institute of Oncology)

  • Marta Guzmán

    (Vall d’Hebron Institute of Oncology)

  • Judit Grueso

    (Vall d’Hebron Institute of Oncology)

  • Cristina Viaplana

    (Vall d’Hebron Institute of Oncology)

  • Javier Hernández

    (Vall d’Hebron Institute of Research (VHIR))

  • Faye Su

    (Novartis Pharmaceuticals)

  • Kui Lin

    (Genentech, Inc., South San Francisco)

  • Robert B. Clarke

    (Breast Biology Group, Manchester Breast Centre)

  • Carlos Caldas

    (Cancer Research UK)

  • Joaquín Arribas

    (CIBERONC, Vall d’Hebron Institute of Oncology
    Vall d’Hebron Institute of Oncology
    Universitat Autònoma de Barcelona
    IMIM (Hospital del Mar Medical Research Institute))

  • Stefan Michiels

    (Service de Biostatistique et d’Epidémiologie, Gustave Roussy
    University Paris-Saclay)

  • Alicia García-Sanz

    (Medica Scientia Innovation Research (MedSIR))

  • Nicholas C. Turner

    (The Breast Cancer Now Research Centre)

  • Aleix Prat

    (August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
    University of Barcelona
    Hospital Clinic
    SOLTI Breast Cancer Research Group)

  • Paolo Nuciforo

    (Vall d’Hebron Institute of Oncology)

  • Rodrigo Dienstmann

    (Vall d’Hebron Institute of Oncology)

  • Chandra S. Verma

    (Bioinformatics Institute (A*STAR)
    Nanyang Technological University
    National University of Singapore)

  • Nuria Lopez-Bigas

    (Institute for Research in Biomedicine (IRB Barcelona)
    Universitat Pompeu Fabra
    Institució Catalana de Recerca i Estudis Avançats (ICREA))

  • Maurizio Scaltriti

    (Memorial Sloan-Kettering Cancer Center)

  • Monica Arnedos

    (Gustave Roussy
    Inserm Unit U981)

  • Cristina Saura

    (Vall d’Hebron Institute of Oncology
    Hospital Vall d’Hebron)

  • Violeta Serra

    (Vall d’Hebron Institute of Oncology
    CIBERONC, Vall d’Hebron Institute of Oncology)

Abstract

No abstract is available for this item.

Suggested Citation

  • Marta Palafox & Laia Monserrat & Meritxell Bellet & Guillermo Villacampa & Abel Gonzalez-Perez & Mafalda Oliveira & Fara Brasó-Maristany & Nusaibah Ibrahimi & Srinivasaraghavan Kannan & Leonardo Mina , 2022. "Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer," Nature Communications, Nature, vol. 13(1), pages 1-1, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34580-3
    DOI: 10.1038/s41467-022-34580-3
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-34580-3
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-34580-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. M. T. Herrera-Abreu & J. Guan & U. Khalid & J. Ning & M. R. Costa & J. Chan & Q. Li & J-P. Fortin & W. R. Wong & P. Perampalam & A. Biton & W. Sandoval & J. Vijay & M. Hafner & R. Cutts & G. Wilson & , 2024. "Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer," Nature Communications, Nature, vol. 15(1), pages 1-19, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34580-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.